Celecoxib treatment alters the gene expression profile of normal colonic mucosa

Oleg K. Glebov; Luz M. Rodriguez; Patrick Lynch; Sherri Patterson; Henry Lynch; Kenneth Nakahara; Jean Jenkins; Janet Cliatt; Casey Jo Humbyrd; John DeNobile; Peter Soballe; Steven Gallinger; Aby Buchbinder; Gary Gordon; Ernest Hawk; Ilan R. Kirsch

doi:10.1158/1055-9965.EPI-04-0866

Celecoxib treatment alters the gene expression profile of normal colonic mucosa

Oleg K. Glebov, Luz M. Rodriguez, Patrick Lynch, Sherri Patterson, Henry Lynch, Kenneth Nakahara, Jean Jenkins, Janet Cliatt, Casey Jo Humbyrd, John DeNobile, Peter Soballe, Steven Gallinger, Aby Buchbinder, Gary Gordon, Ernest Hawk, Ilan R. Kirsch

Department of Preventive Medicine

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is

Original language	English (US)
Pages (from-to)	1382-1391
Number of pages	10
Journal	Cancer Epidemiology Biomarkers and Prevention
Volume	15
Issue number	7
DOIs	https://doi.org/10.1158/1055-9965.EPI-04-0866
State	Published - Jul 2006

All Science Journal Classification (ASJC) codes

Epidemiology
Oncology

Access to Document

10.1158/1055-9965.EPI-04-0866

Cite this

Glebov, O. K., Rodriguez, L. M., Lynch, P., Patterson, S., Lynch, H., Nakahara, K., Jenkins, J., Cliatt, J., Humbyrd, C. J., DeNobile, J., Soballe, P., Gallinger, S., Buchbinder, A., Gordon, G., Hawk, E., & Kirsch, I. R. (2006). Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiology Biomarkers and Prevention, 15(7), 1382-1391. https://doi.org/10.1158/1055-9965.EPI-04-0866

Glebov, OK, Rodriguez, LM, Lynch, P, Patterson, S, Lynch, H, Nakahara, K, Jenkins, J, Cliatt, J, Humbyrd, CJ, DeNobile, J, Soballe, P, Gallinger, S, Buchbinder, A, Gordon, G, Hawk, E & Kirsch, IR 2006, 'Celecoxib treatment alters the gene expression profile of normal colonic mucosa', Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 7, pp. 1382-1391. https://doi.org/10.1158/1055-9965.EPI-04-0866

@article{d6a80fdf9ba245b481d2df92c0ea8d6e,

title = "Celecoxib treatment alters the gene expression profile of normal colonic mucosa",

abstract = "A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is ",

author = "Glebov, {Oleg K.} and Rodriguez, {Luz M.} and Patrick Lynch and Sherri Patterson and Henry Lynch and Kenneth Nakahara and Jean Jenkins and Janet Cliatt and Humbyrd, {Casey Jo} and John DeNobile and Peter Soballe and Steven Gallinger and Aby Buchbinder and Gary Gordon and Ernest Hawk and Kirsch, {Ilan R.}",

year = "2006",

month = jul,

doi = "10.1158/1055-9965.EPI-04-0866",

language = "English (US)",

volume = "15",

pages = "1382--1391",

journal = "Cancer Epidemiology Biomarkers and Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - Celecoxib treatment alters the gene expression profile of normal colonic mucosa

AU - Glebov, Oleg K.

AU - Rodriguez, Luz M.

AU - Lynch, Patrick

AU - Patterson, Sherri

AU - Lynch, Henry

AU - Nakahara, Kenneth

AU - Jenkins, Jean

AU - Cliatt, Janet

AU - Humbyrd, Casey Jo

AU - DeNobile, John

AU - Soballe, Peter

AU - Gallinger, Steven

AU - Buchbinder, Aby

AU - Gordon, Gary

AU - Hawk, Ernest

AU - Kirsch, Ilan R.

PY - 2006/7

Y1 - 2006/7

N2 - A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is

AB - A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is

UR - http://www.scopus.com/inward/record.url?scp=33746411410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746411410&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-04-0866

DO - 10.1158/1055-9965.EPI-04-0866

M3 - Article

C2 - 16835340

AN - SCOPUS:33746411410

VL - 15

SP - 1382

EP - 1391

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -

Celecoxib treatment alters the gene expression profile of normal colonic mucosa

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this